Pharmagreen Biotech Stock Performance
| PHBI Stock | USD 0 0.0002 16.67% |
On a scale of 0 to 100, Pharmagreen Biotech holds a performance score of 1. The company holds a Beta of 2.32, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pharmagreen Biotech will likely underperform. Please check Pharmagreen Biotech's jensen alpha, accumulation distribution, relative strength index, as well as the relationship between the value at risk and day typical price , to make a quick decision on whether Pharmagreen Biotech's historical price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Pharmagreen Biotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly fragile fundamental drivers, Pharmagreen Biotech demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 25.3 K | |
| Free Cash Flow | -426.6 K |
Pharmagreen |
Pharmagreen Biotech Relative Risk vs. Return Landscape
If you would invest 0.16 in Pharmagreen Biotech on December 23, 2024 and sell it today you would lose (0.02) from holding Pharmagreen Biotech or give up 12.5% of portfolio value over 90 days. Pharmagreen Biotech is currently generating 0.2099% in daily expected returns and assumes 9.5838% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of pink sheets are less volatile than Pharmagreen, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pharmagreen Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharmagreen Biotech's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Pharmagreen Biotech, and traders can use it to determine the average amount a Pharmagreen Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0219
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PHBI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.58 actual daily | 85 85% of assets are less volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Pharmagreen Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharmagreen Biotech by adding it to a well-diversified portfolio.
Pharmagreen Biotech Fundamentals Growth
Pharmagreen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Pharmagreen Biotech, and Pharmagreen Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharmagreen Pink Sheet performance.
| Return On Asset | -2.3 | |||
| Current Valuation | 3.12 M | |||
| Shares Outstanding | 454.76 M | |||
| EBITDA | (828.26 K) | |||
| Cash And Equivalents | 24.26 K | |||
| Total Debt | 119.47 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (426.57 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 208.97 K | |||
About Pharmagreen Biotech Performance
By evaluating Pharmagreen Biotech's fundamental ratios, stakeholders can gain valuable insights into Pharmagreen Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pharmagreen Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharmagreen Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Pharmagreen Biotech Inc., a biotech sciences solutions company, focuses on the production of starter plantlets for CBD hemp and medical cannabis industries. The company was incorporated in 2007 and is headquartered in Coquitlam, Canada. Pharmagreen Biotech is traded on OTC Exchange in the United States.Things to note about Pharmagreen Biotech performance evaluation
Checking the ongoing alerts about Pharmagreen Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Pharmagreen Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharmagreen Biotech had very high historical volatility over the last 90 days | |
| Pharmagreen Biotech has some characteristics of a very speculative penny stock | |
| Pharmagreen Biotech currently holds 119.47 K in liabilities. Pharmagreen Biotech has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Pharmagreen Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Pharmagreen Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pharmagreen Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pharmagreen to invest in growth at high rates of return. When we think about Pharmagreen Biotech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (875.48 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pharmagreen Biotech currently holds about 24.26 K in cash with (426.57 K) of positive cash flow from operations. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pharmagreen Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharmagreen Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Pharmagreen Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharmagreen Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharmagreen Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharmagreen Biotech's pink sheet. These opinions can provide insight into Pharmagreen Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pharmagreen Pink Sheet analysis
When running Pharmagreen Biotech's price analysis, check to measure Pharmagreen Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagreen Biotech is operating at the current time. Most of Pharmagreen Biotech's value examination focuses on studying past and present price action to predict the probability of Pharmagreen Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagreen Biotech's price. Additionally, you may evaluate how the addition of Pharmagreen Biotech to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance |